Opendata, web and dolomites


Chemically synthesised novel compounds for the stabilisation of biologics

Total Cost €


EC-Contrib. €






 ExtremoChem project word cloud

Explore the words cloud of the ExtremoChem project. It provides you a very rough idea of what is the project "ExtremoChem" about.

humira    organic    lower    obtain    purification    biologic    volume    extremochem    once    stabilise    elaborate    proteins    stressful    subject    stability    insulins    agitation    small    aggregation    synthetic    stages    industrial    restored    blood    extraction    safety    biopharmaceuticals    critical    business    reachable    medicines    market    size    source    strict    prepare    trial    issue    assuring    20    preserve    least    neupogen    drugs    commercial    biopharmaceutical    synthesises    cells    interferins    protects    biotechnology    share    cold    rheumatoid    chain    molecules    sign    tests    savings    carbons    temperatures    mabs    validation    full    vaccines    stabilization    lost    potency    feasible    medical    ph    sensitive    degradation    arthritis    material    direct    revenues    white    salinity    biological       otherwise    preventing    thermally    consisting    12    sound    suitable    biologics    degrade    plan    quality    native    storage    compounds    wasted    clinical    line    effectiveness   

Project "ExtremoChem" data sheet

The following table provides information about the project.


Organization address
address: Estrada Municipal 528, 1
postcode: 7040-220
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-03-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EXTREMOCHEM LDA PT (IGREJINHA) coordinator 50˙000.00


 Project objective

Biologics are medical drugs produced using biotechnology, other than direct extraction from a native biological source. Many of biopharmaceutical products are subject to very strict production, storage and distribution requirements in order to preserve effectiveness and safety. Biopharmaceuticals stability is a key issue in assuring that these medicines maintain their quality, safety and full potency. Once potency is lost, it cannot be restored, this means the biologic is wasted.

ExtremoChem synthesises a line of novel compounds consisting of synthetic small organic molecules, from 8 to 12 carbons, that are able to stabilise proteins and other biological material by preventing their degradation under stressful conditions, such as higher or lower temperatures, pH, salinity, agitation under which they would otherwise degrade. eXtremochem is suitable for a wide range of proteins such as mAbs, vaccines, insulins, interferins and etc. But ExtremoChem currently focuses on mAbs, such as Humira (for rheumatoid arthritis) & Neupogen (for growth of white blood cells), since they present a high value market. The eXtremochem compounds improve the stability of molecules in the most critical purification stages and protects biologics, preventing aggregation and increasing production volume by 20%. Furthermore, eXtremochem enables long-term storage of thermally sensitive biologics without the need for cold chain, thus bringing significant savings to biopharmaceuticals – 6.5% of their revenues.

The Phase 1 project will allow ExtremoChem to evaluate the medicines’ degradation under the presence of the small organic molecules through several stabilization tests, prepare a feasible industrial scale-up plan, plan a sound Ph 1 clinical trial, elaborate the business scale up, and size the reachable market and a reliable market share. Within the overall project, ExtremoChem aims to: obtain the clinical validation and sign at least one commercial agreement.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EXTREMOCHEM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EXTREMOCHEM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More